Question Bank › Recently unlocked door

Recently unlocked door

Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business

Calls Tested
499
Answered YES
24
Hit Rate
4.8%
rare by design

Zimmer Biomet Holdings, Inc. (ZBH) — this company's answers

NO on the Q2 2017 call 2017-07-30 F
The model's full reasoning — Q2 2017 call → NOWe need answer YES/NO. Need analyze transcript. Question asks: Does management describe that company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something granted by outside authority, customer, partner, or institution that newly allows company to sell, serve, or operate where previously could not — AND that real first business through that newly opened door has ALREADY BEGUN, with most of what access permits still ahead? Need use only transcript. Look for regulatory clearance, launch, etc. In transcript: "Additionally, we have received regulatory clearance in the U.S. to market our clinical graphics technology for femoroacetabular impingement. This platform enhances our hip preservation portfolio with 3D range of motion simulation software designed to inform treatment decisions." That is a permission/approval recently obtained? Received regulatory clearance in U.S. to market technology. Did first business already begin? Management doesn't say sales have begun. It just says received clearance. No mention of first business flowing. Also "During the quarter, our limited launch of the Persona Partial Knee received excellent early clinical feedback from surgeons. We expect to begin the full commercial launch of this product later this quarter." That is a launch, but is it a permission/approval? It's a product launch, not necessarily newly obtained access right? It may be a new product, but question asks permission/approval/qualification etc. Persona Partial Knee limited launch? It says limited launch received feedback, expect full commercial launch later this quarter. That implies product is being sold in limited launch? But is that "recently obtained permission"? Not explicitly. Also "commercial availability in certain European markets of our X-PSI guides, the world’s first CE Mark surgical planning system..." CE Mark is regulatory approval. "During the quarter, we announced the commercial availability in certain European markets of our X-PSI guides, the world’s first CE Mark surgical planning system..." That is a permission/approval (CE Mark) recently obtained? It says announced commercial availability, CE Mark. First business already flowing? "commercial availability" suggests it is available, but no mention of actual sales/revenue.

← Back to the full ZBH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something granted by an outside authority, customer, partner, or institution that newly allows the company to sell, serve, or operate where it previously could not — AND that real first business through that newly opened door has ALREADY BEGUN, with most of what the access permits still ahead? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) the access is REAL AND RECENTLY IN HAND — granted, completed, or effective within roughly the last few quarters, not pending, applied-for, or expected; the form may be a regulatory approval or clearance, a customer or platform qualification, a certification or accreditation, a license, a formulary or program listing, entry onto an approved-supplier roster, or any equivalent gate that previously excluded the company; (2) FIRST BUSINESS IS ALREADY FLOWING — actual initial orders, customers, shipments, enrollments, placements, or revenue attributable to the new access, occurring now, however small; and (3) management conveys that what the access opens is LARGE RELATIVE TO WHAT HAS FLOWED SO FAR — the population, market, or activity now reachable is mostly unserved, so the reported results reflect only the first trickle through the door. Answer NO if the access is still pending, hoped for, or contingent. NO if the gate was cleared but nothing has yet transacted through it. NO if the access is routine renewal of permissions the company has long held. NO if the business through the new access is already mature and substantially reflected in results. NO if the door and its significance appear only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
RDCM RADCOM Ltd. Q4 2023 2024-01-31 A
PFE Pfizer Inc. Q4 2023 2024-01-30 F
NVAX Novavax, Inc. Q3 2023 2023-11-09 F
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
CMLS Cumulus Media Inc. Q3 2022 2022-10-28 D
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
CDXC ChromaDex Corporation Q4 2021 2022-03-09 C+
VNDA Vanda Pharmaceuticals Inc. Q4 2021 2022-02-23 F
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
AMGN Amgen Inc. Q3 2018 2018-10-30 B+
MAS Masco Corporation Q3 2018 2018-10-30 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
BMY Bristol-Myers Squibb Company Q4 2016 2017-01-26 F
MAT Mattel, Inc. Q3 2016 2016-10-19 C

How the model reasoned

NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.

More from the question bank

Paid to expand: the company's growth spendinTwo-sided intensityNamed catch-up gapNew leadership already changing what the comThe product is disappearing into reorder rhyComing out of the tunnelAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.